---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-003726"
form_type: "8-K"
ticker: null
cik: "0001429560"
company_name: "TREVENA INC"
filed_at: "2026-01-14T23:59:59+00:00"
generated_at: "2026-05-16T10:24:07.788481+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Trevena terminates royalty loan by assigning China license to R-Bridge; all debt discharged

## Summary
- Agreement dated Jan 9, 2026 with R-Bridge, Nhwa: royalty loan obligations released in exchange for China license rights (except milestones).
- Trevena transfers all rights under China License Agreement to R-Bridge; Nhwa consents, future royalties (except milestones) paid to R-Bridge.
- Loan Agreement and all security interests terminated; Trevena SPV1, SPV2, Royalty LLC released from obligations.
- China License Agreement term extended to 10 years after first commercial sale (June 30, 2033), with possible renewal.
- Trevena discontinued US commercialization of Olinvyk; covenants to enter new safety data exchange if resumed.

## SEC filing metadata
- accession: 0001104659-26-003726
- form_type: 8-K
- cik: 0001429560
- company_name: TREVENA INC
- filed_at: 2026-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429560/000110465926003726/0001104659-26-003726-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429560/000110465926003726/tm263115d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-003726
- JSON: https://secwatch.observer/filing/0001104659-26-003726.json
- Plain text: https://secwatch.observer/filing/0001104659-26-003726.txt

## Key facts
- Material Agreements
  TREVENA INC terminated License Agreement with Jiangsu Nhwa Pharmaceutical Co. Ltd. and R-Bridge Investment Four Pte. Ltd. (effective 2026-01-09).
  - Action: termination
  - Agreement: credit facility
  - Counterparty: Jiangsu Nhwa Pharmaceutical Co. Ltd. and R-Bridge Investment Four Pte. Ltd.
  - Effective: 2026-01-09
  source text: On January 9, 2026, Trevena, Inc., Trevena SPV2 LLC, Trevena SPV1 LLC, and Trevena Royalty LLC (collectively the “Company”) entered into an Assignment and Release Agreement (the “Agreement) with Jiangsu Nhwa Pharmaceutical Co. Ltd. (“Nhwa”) and R-Bridge Investment Four Pte. Ltd., (the “Lender”) whereby the Lender agreed to terminate and release the Company from all obligations
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429560/000110465926003726/0001104659-26-003726-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.